Arvinas, a preclinical biotech developing protein degradation therapies for metastatic cancers, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
The New Haven, CT-based company was founded in 2013 and booked $12 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol ARVN. Arvinas filed confidentially on June 22, 2018. Goldman Sachs, Citi and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
